Skip to main content
SpringerLink
Log in

SMC publishes latest recommendations

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Scottish Medicines Consortium. SMC advice: aflibercept (Eylea); brinzolamide and brimonidine (Simbrinza); daclatasvir (Daklinza); everolimus (Afintor); ipilimumab (Yervoy); mifepristone (Medabon); pertuzumab (Perjeta); saxagliptin (Onglyza). Internet Document : 13 Nov 2014. Available from: URL: http://www.scottishmedicines.org.uk/Home

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SMC publishes latest recommendations. PharmacoEcon Outcomes News 716, 30 (2014). https://doi.org/10.1007/s40274-014-1724-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1724-z

Search

Navigation